{"data":{"id":"us/21-cfr-522.2065","jurisdiction":"us","citation":"21 CFR 522.2065","heading":"Rabacfosadine.","body":"(a) Specifications. Each vial of powder contains 16.4 milligrams (mg) rabacfosadine. Each milliliter of constituted solution contains 8.2 mg rabacfosadine.\n(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter.\n(c) Conditions of use in dogs—(1) Amount. Administer rabacfosadine at 1 mg/kilogram body weight as a 30-minute intravenous infusion, once every 3 weeks, for up to 5 doses.\n(2) Indications for use. For the treatment of lymphoma in dogs.\n(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.","path":["Title 21—Food and Drugs","CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER E—ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS","PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-21.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:24:47Z","sha256":"71000918eeeb1ab4bf9cbb4d13f8395e1ef22330875d526fd8ea7c1a218eda45","source_id":"us-cfr","stale":true,"prev":"us/21-cfr-522.2063","next":"us/21-cfr-522.2075"},"notice":"GroundRules: Original legal text. Not legal advice."}